Regulators of G protein signaling accelerate GTP hydrolysis by Ga subunits and profoundly inhibit signaling by G protein-coupled receptors. The distinct expression patterns and pathophysiologic regulation of regulators of G protein signaling proteins suggest that inhibitors may have therapeutic potential. We previously reported the design, mechanistic evaluation, and structure-activity relationships of a disulfide-containing cyclic peptide inhibitor of RGS4, YJ34 (Ac-Val-Lys-c[Cys-ThrGly-Ile-Cys]-Glu-NH 2 , S-S) (Roof et al., Chem Biol Drug Des, 67, 2006, 266). Using a focused onebead, one-compound peptide library that contains features known to be necessary for the activity of YJ34, we now identify peptides that bind to RGS4. Six peptides showed confirmed binding to RGS4 by flow cytometry. Two analogs of peptide 2 (GlyThr-c[Cys-Phe-Gly-Thr-Cys]-Trp-NH 2 , S-S with a free or acetylated N-terminus) inhibited RGS4-stimulated Ga o GTPase activity at 25-50 lM. They selectively inhibit RGS4 but not RGS7, RGS16, and RGS19. Their inhibition of RGS4 does not depend on cysteine-modification of RGS4, as they do not lose activity when all cysteines are removed from RGS4. Peptide 2 has been modeled to fit in the same binding pocket predicted for YJ34 but in the reverse orientation.
There have been over 30 RGS proteins identified (20) , which are divided into eight families (RZ, R4, R7, R12, RA, GEF, GRK, and SNX families) based on the homology of the 120 amino acid RGS domain as well as the presence or absence of other domains (1) . The R4 family contains the RGS domain as well as an amphipathic N-terminus (21, 22) that plays a role in membrane targeting and ⁄ or receptor specificity (21) (22) (23) . RGS4 is the prototypical member of the R4 family. It has roles in cardiovascular and central nervous system signaling and was the starting point for our RGS inhibition efforts.
We previously reported the first RGS inhibitor, YJ34 (Ac-Val-Lysc[Cys-Thr-Gly-Ile-Cys]-Glu-NH 2 , S-S) (24) . This peptide was designed to mimic the switch 1 region of the Ga subunit and was modeled from the RGS4-Ga i1 crystal structure (25) . It has a sequence similar to the switch 1 region with two amino acid substitutions (Thr181 to Cys and Val185 to Cys) to incorporate a disulfide bridge, which constrains the peptide in the correct conformation (24, 26) . This peptide has an IC 50 of 26 lM in a membrane-based steady state GTPase assay (24) , a 9 lM IC 50 in a purified protein single turnover GTPase assay (26) , inhibits RGS4 81% at 40 lM in a capillary electrophoresis assay (27) , and an analog inhibits RGS modulation of G-protein inwardly rectifying potassium current kinetics in atrial myocytes (26) . It has been found that BR2 (Ac-Val-Lys-c[Cys-Thr-Ser-Ile-Cys]-Glu-NH 2 , S-S), a peptide that mimics the RGS-insensitive G184S mutation in the Ga protein, is inactive, suggesting that YJ34 binds to RGS4 as designed (i.e., in the same way that the Ga switch 1 binds). Structure-activity relationship studies on this peptide showed that the following features were necessary for peptide activity: the N-terminal acetyl group, C-terminal amide, the Gly at position 5, and Cys residues at positions 3 and 7 linked by a disulfide bridge (26) .
Peptide YJ34 is a useful tool for studying RGS function, but we wanted to find other, hopefully more potent, RGS inhibitors. We report here the use of a focused one-bead, one-compound (OBOC) (28) peptide library to screen for RGS4 inhibitors. The library was restricted to contain peptides with the features mentioned above that are required for the function of YJ34. The other five amino acids were randomized among the 19 natural amino acids (except Cys) to afford 2.5 million possible peptide sequences. The library was synthesized and screened for RGS4 binding using beads containing only one peptide sequence each. Half of the peptides on each bead had an acetyl group, because it is important for peptide YJ34 function, while half had a free N-terminus, to allow sequencing by Edman degradation. From this screen, we identified seven peptide sequences that bound RGS4. Two analogs of peptide 2, 2ad (Ac-Gly-Thr-c[Cys-Phe-Gly-Thr-Cys]-Trp-NH 2 , S-S) and 2nd (Gly-Thr-c[Cys-Phe-Gly-Thr-Cys]-Trp-NH 2 , S-S) are novel inhibitors of RGS4.
Materials and Methods

Materials
Fmoc-protected amino acids and Rink amide resin were purchased from Advanced ChemTech (Louisville, KY, USA). Fmoc protected and acetylated amino acid purity was verified by high performance liquid chromatography (HPLC). Tentagel Resin was purchased from ChemImpex (Wood Dale, IL, USA) or Rapp-Polymer (Tubingen, Germany), and Alexa Fluor label from Invitrogen (Carlsbad, CA, USA). Peptide synthesis grade chemicals were purchased from either Applied Biosystems (Foster City, CA, USA) or Sigma-Aldrich (St Louis, MO, USA). c[ 32 P]GTP (10 mCi ⁄ mL) was purchased from Perkin Elmer (Boston, MA, USA) and diluted with unlabeled GTP to the desired level of radioactivity. Amylose resin was purchased from New England Biolabs and the Ni-NTA resin from Qiagen.
Protein expression, purification, and labeling His 6 -Ga o (rat) and RGS4D18N (rat), were expressed and purified according to previous protocols (29) (30) (31) (32) . Mbp-His 6 -RGS4D51N (human), Mbp-His 6 -RGS16 (human), Mbp-His 6 -RGS19D11C (human), Mbp-His 6 -RGS7 RGS domain (human, nucleotides 915-1359), and the mutant Mbp-His 6 -RGS4D51N lacking all seven cysteines (called '-7C') were in Gateway pMAL vectors and were expressed using a similar protocol as the RGS4D18 construct and purified over an amylose column followed by an Ni-NTA column according to the manufacturer's protocol. In some cases, this was followed by a size exclusion column as necessary. The mutagenesis was carried out using the 'QuickChange Multi Site-Directed Mutagenesis Kit' from Stratagene according to the manufacturer's protocol. Labeling of RGS4 with succinimide ester fluorophores (Alexa Fluor 568 and Alexa Fluor 532) was performed according to the manufacturer's protocol using approximately twofold to threefold excess fluorophore.
OBOC peptide library synthesis
The protocol was based on previous reports (28,33) using a manual 'mix and split' synthesis. TentaGel amide resin (10 g of 130 lm-sized beads with a substitution level of 300 pmol) was swelled in N-methylpyrrolidone (NMP) and divided by volume into 19, 8.0-mL polypropylene filter columns (Alltech, Deerfield, IL, USA). To each column, a solution of a different Fmoc-protected amino acid in NMP was added; all natural amino acids were used except cysteine. This was followed by a solution containing a threefold excess 2-(1H-Benzotriazole-1-yl)-1,1,3,3,-tetramethylaminium hexafluorophosphate ⁄ 1-hydroxybenzotria-zole (HBTU ⁄ HOBt) and 2 M N,N¢-diisopropylethylamine (DIEA) in NMP and the mixture was shaken for 1 h at room temperature. Then the beads were rinsed thoroughly with NMP. Unreacted amino groups on the resin were acetylated with a 20-fold excess of acetic anhydride with DIEA and HOBt in NMP. After a negative bromophenol blue test for free amines, the beads were pooled and treated with 50% piperidine in NMP. The splitting, coupling, pooling, and deprotection (but not the acetylation) steps were repeated for the randomized positions. For the non-random positions, the resin was not split and Fmoc-Cys(trt)-OH (position 3 or 7) or Fmoc-Gly-OH (position 5) was coupled to the whole batch of beads. In the final coupling step, a 1:1 mixture of acetylated and Fmocprotected amino acids was used. To remove the side chain protecting groups without cleaving the peptide from the resin (33) , all the beads were pooled and treated with 50 mL ice-cold 88:5:5:2 trifluoroacetic acid (TFA):phenol:water:triisopropylsilane (TIPS) and shaken for 3 h at room temperature. Treatment of test peptides with deprotection reagents resulted in no detectable cleaved peptide as checked by HPLC. After thorough washing (including a wash in 10% DIEA to neutralize obtained TFA salts), the resin was added to 7.8-L oxidation solution [20% Dimethylsulfoxide (DMSO), 5% Acetic acid, in water pH 6.0 purged of air with N 2 ] and shaken for 48 h.
Library screening
Beads were washed and plated in a single layer (on an average, approximately 1500 beads per well) in 96-well plates in buffer (1% BSA in 20 mM Hepes pH 8.0) and incubated with 25 nM RGS4D18N-Alexa Fluor 568. Wells containing beads with YJ34 were included in every scan as a control. Fluorescence was imaged on a Typhoon 9200 Gel Imager using an excitation of 532 nm and an emission of 610 nm and the fluorescence was quantified with the accompanying ImageQuant software. To do this, a 12 · 8 grid was placed over the image such that each grid block contained only one well. Grid blocks that contained an object with intensity more than 5-to 10-fold over the most intense object in the wells containing YJ34 were collected and pooled. The image was visually inspected and any objects that were clearly not beads, such as dust or other debris, were excluded. Pooled beads were washed with buffer, diluted, and rescreened against 10 nM RGS4D18N-Alexa Fluor 568. The process was repeated with lower RGS4 concentrations until a single bead per well was obtained. The top 20 hits were then isolated with a needle under a dissecting microscope and sent for sequencing by Edman degradation at the Biomedical Research Core Facilities at the University of Michigan.
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Synthesis of individual peptides
Soluble (not bead-bound) peptides (for GAP assays) were synthesized on Rink resin, cleaved from the resin and cyclized as described previously (24, 26) . Peptide purity (at least 95%) and solubility were verified by HPLC and correct mass was verified by mass spectrometry analysis (26) . YJ34 and BR2 bead-bound controls were synthesized on 130 lm Tentagel resin using the same protocol as the library except that no 'mix and split' steps were incorporated. Hit peptides on beads (for the FACScan assays) were synthesized on 20 lm Tentagel resin using a LabMate apparatus (Advanced ChemTech) and cyclized manually using the similar chemistries as for the library with no 'mix and split' randomization. The deprotection mixture was 83:5:5:5:2 TFA:thioanisole:phenol:TIPS and an Ellman test was performed to ensure complete oxidation.
Binding of test peptides
Unreacted 130 lm TentaGel amide resin, or resin containing YJ34 or BR2 was put into wells of a 96-well plate with 5 mg per well in 0.5 mL buffer (1% BSA in 20 mM Hepes pH 8.0) for 1 h. The supernatant was removed and various concentrations of Alexa Fluor 568 labeled RGS4D18N were added in 200 lL followed by incubation for 15 min. After a wash with 500 lL buffer, fluorescence was measured in black Costar 96-well plates in a Victor 2 fluorescence plate reader with an excitation filter at 560 and an emissions filter at 595. Samples were measured in duplicate.
FACScan flow cytometry
Peptide beads (about 5 · 10 3 per sample for a maximum of 5 nmol peptide) were washed and then incubated with 25 nM RGS4D51N-Alexa Fluor 532 in 300 lL for at least 15 min at room temperature under foil. The Becton Dickinson FACScan was gated and the laser intensity set in CellQuest such that control beads (acetylated TentaGel resin) were gated and had low but measurable fluorescence. No compensation was set. Fluorescence of RGS4D51N-Alexa Fluor 532 bound to acetylated beads (about 60% of YJ34 beads) was considered background and subtracted from all samples. Samples were read in duplicate.
RGS-stimulated GTPase
Single turnover GTP hydrolysis measurements with and without RGS were performed as described previously (26) .
Modeling
Peptides were modeled using Quanta (Accelrys Inc., San Diego, CA, USA) by modifying the residues from the Ga i1 switch 1 in the RGS4-Ga i1 (PDB entry: 1agr) crystal structure (25) . Upon residue substitution and formation of the disulfide bond, energy minimization of each peptide with all hydrogen atoms added was performed using the QUANTA ⁄ CHARMM simulation package (Accelrys) with dielectric constant () = 10 and the Adopted-Basis Newton Raphson method (50 steps). To model the peptide-RGS complex, each minimized peptide with the hydrogens removed was substituted for the corresponding Ga i fragment from the Ga i -RGS4 complex. Images were prepared using PyMol for OS X (http://www.pymol.org).
Statistical analysis
Data are expressed as mean € SEM (or € SD for n = 2) and analyzed by either a t-test (GAP data) or a one-way ANOVA (Victor-based test binding and FACScan data). A Bonferroni post-test was carried out on the FACScan data. Significance is indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001.
Results and Discussion
OBOC library design and screening It has been found previously that several structural features were necessary for activity of YJ34: the N-terminal acetyl group, the C-terminal amide, Gly at position 5, and Cys at positions 3 and 7 with their side chains linked via a disulfide bridge. However, the other five positions can be varied (26) . As seen in Table 1 , the features necessary for YJ34 function were constrained in the library, while the other positions were randomized. All natural amino acids except Cys were used in the other five positions to give 2.5 million possible sequences. Using 10 g of 130 lm TentaGel beads provides approximately 7.9 million beads; thus each sequence would have The key features of YJ34 were constrained in the library. The library had the Gly at position 5, the Cys at positions 3 and 7 with a disulfide bonds, and a C-terminal amide. The other five amino acid positions were randomized such that each bead had only one sequence. Half of the peptides on each bead had an acetyl group and the other half had a free N-terminus. There were 300 pmol peptide on each bead, 2.5 million sequences, and 7.9 million beads in the library.
Novel Peptide RGS4 Inhibitors been present on three beads in the library, on an average. In an OBOC library, each bead has only one amino acid sequence. However, for this library, half of the peptides on each bead were acetylated, as this is necessary for the function of YJ34, and half had a free N-terminus, to allow sequencing by Edman degradation. The beads had a substitution level of 300 pmol per bead, resulting in about 150 pmol of free-amine-containing peptides for sequencing. This was found to be sufficient for sequencing of test peptides (data not shown). In addition, as a control, we ensured that YJ34 on beads bound to RGS4 (Figure 1 ). Although TentaGel resin is known not to be cleavable with TFA treatment (33), it was verified that deprotection conditions did not remove test peptides from resin (see Methods). Tentagel resin was chosen because it has been used extensively and has good mechanical stability and has a uniform size. Unfortunately, it has green autofluorescence (34), and so a red dye (Alexa Fluor 568) was chosen for RGS4 labeling for the library screen. Others have found non-specific binding to be problematic with this resin (Anna Mapp, personal communication, 2008). We did find high non-specific binding to unreacted resin (data not shown), but this was not observed with acetylated resin or with resin containing BR2 [Ac-Val-Lys-c[Cys-Thr-Ser-Ile-Cys]-Glu-NH 2 , S-S, which is an inactive peptide that mimics the RGS insensitive mutation in the Ga protein (26)].
To screen the library, the beads were incubated with Alexa Fluor 568 labeled RGS4D18N and imaged in a Typhoon Gel Imager as shown in Figure 2 . The top 20 most fluorescent beads were isolated and sequenced by Edman degradation. Unfortunately, six of the hits yielded only partial sequences, leaving 14 fully sequenced hits for further evaluation.
Hit verification
Each of the 14 sequenced hit peptides was resynthesized on 20 lm TentaGel beads. As both were present in the library, free N-terminal, disulfide bridged (nd) and acetylated, disulfide bridged (ad) versions of each sequence were synthesized. Interaction with Alexa Fluor 532 labeled RGS4D51N was detected in a FACScan Flow Cytometer (Figure 3) . The RGS4D51N protein lacking the amphipathic helix in the N-terminus was used to ensure that the verified hits bound to the RGS domain of RGS4. Using 2.5-fold increased binding of RGS4D51N-Alexa Fluor 532 compared with YJ34 on beads as a cut-off, it was found that some of the initial hits were false positives, but peptides 1, 2, 3, 4, 7, 11, and 14 ( Figure 3 , Table 2 ) were verified and were chosen for further evaluation. The hits were structurally divergent from our lead compound. Both the free N-terminal and the acetylated versions of the verified hits bound RGS4D51N. This is in contrast to YJ34, where only the acetylated version has activity in the GAP assay (26) . 
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Peptide activity in GAP assays
Peptides were tested at 50 lM except for YJ34, 2ad, and 14nd, which were limited by solubility. Effects on the rate of RGS-stimulated Gao GTPase activity were measured in a single turnover assay with purified proteins and peptides in solution (Figure 4 ). Hit 11 was not evaluated because of signs of aggregation. Only peptides 2nd (the free N-terminal, disulfide bridged hit 2) and 2ad (the acetylated, disulfide bridged peptide 2) had statistically significant inhibition of RGS4 activity (48 € 7% inhibition at 50 lM and 30 € 12% inhibition at 25 lM, respectively). Based on these values, both peptides have an estimated IC 50 of about 50 lM. Other peptides that had some activity included 1nd (33 € 15% inhibition at 50 lM) and 4nd (33 € 16% inhibition at 50 lM, Figure 4 ). The activity of hit 2 was investigated further in Figure 5 . Linear as well as disulfide bridged versions of peptide 2 (2nl: free N-terminal linear and 2al: acetylated linear) were tested in the GAP assay, as cyclization yields may have been less than 100% in the synthesis of the library leaving some linear peptides present on each bead, which may have contributed to the observed fluorescence of the bead ( Figure 5A ). Consistent with previous results for YJ34, the linear peptides were inactive. Regulators of G protein signaling selectivity was also investigated. Interestingly, peptides 2ad and 2nd were inactive against RGS7, RGS16, and RGS19 ( Figure 5B ). The RGS16, like RGS4, is in the R4 family, while RGS7 and RGS19 are in different families (R7 and RZ, respectively) and have lower homology with RGS4.
Recently, CCG-4986, a small molecule inhibitor of RGS4 was identified and found to interact with RGS4 through cysteine modification [(32,35) , David Roman, unpublished observation]. For this reason, the activity of our original peptide, YJ34, as well as that of hit 2 was evaluated with an RGS4D51N mutant lacking all seven cysteines (-7C) ( Figure 5C ). The -7C mutant was inhibited by 2ad, 2nd, and YJ34. There was no statistically significant difference between the activity on wild type and the -7C RGS4D51N for 2ad, 2nd or YJ34 (59 € 4%, 27 € 7%, 60 € 11% inhibition for 2ad, 2nd, and YJ34, respectively). This indicates that hit 2 does not inhibit RGS4 through cysteine modification. 
Peptides from Figure 3 that bind RGS4D51N-Alexa Fluor 532 at least 2.5-fold more than YJ34 are shown. Note that both acetylated, disulfide bridged (ad) and free N-terminal, disulfide bridged (nd) peptides were chosen for further evaluation. Rates were calculated based on the time courses, and percent decrease in the rate of RGS-stimulated GTP hydrolysis by peptides was measured (mean € SEM, n ‡ 3). *p < 0.05, **p < 0.01, ***p < 0.001 compared with no peptide.
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Conclusions
Inhibition of protein-protein interactions (PPIs) is particularly challenging. Unlike enzymes and receptors that have well-defined pockets, protein-protein interfaces tend to be large and flat (36) . Because of this, many PPIs have been declared 'non-amenable' to inhibition by drug-like molecules based on computational measurements (37) . In fact, the RGS4-Ga o interaction falls in this category (David Fry, personal communication, 2006) . However, some proteinprotein interfaces have been found to have 'hot spots', which are a limited number of residues that are responsible for the majority of the interaction energy. Others have taken advantage of this to successfully create peptide and small molecule inhibitors of PPIs (38) (39) (40) . In addition, computational approaches such as those used in Fry and Vassilev (37) are based on rigid crystal structures of proteins. Others have shown that protein interfaces are adaptable and in multiple cases, small molecules bind in induced pockets that are not observed in the crystal structures of the protein alone or in complex with its natural protein-binding partner [(41) and references therein]. Thus, these interactions could not be rationally predicted in spite of the existence of a structure of the target protein and could only come from experimental screening. Hence, although this was an ambitious project, there are ample precedents for success. In fact, the above-mentioned small molecule inhibitor of RGS4, CCG-4986, was found in a screen to block the RGS4-Gao interaction (32) . Inhibitors of RGS4 were also found in a yeast-based screen, but unfortunately, no structures were reported (42) .
Of the seven RGS4-binding peptides found in our OBOC peptide library screen, one peptide sequence (in both free amide and acetylated form) was found to inhibit RGS4 GAP activity in the single turnover GAP assay. Although the potency of the new compounds is no greater then the starting peptide, we have identified new peptides that we believe have the desired mode of binding to RGS4, and the desired RGS4 inhibitor activity.
Based on the crystal structure of RGS4 bound to Ga i (25) , Thr182 of Ga i forms hydrogen-bonding and hydrophobic interactions with several residues in RGS4 including Asn88, Asp163, Ser164, and Leu159. The corresponding residue in YJ34, Thr
4
, may similarly interact with RGS4 residues. However, there is a Phe at this position in peptide 2 and it is unlikely that this bulkier, non-polar side chain interacts with RGS in the same manner as does the Thr 4 side chain of YJ34 ( Figure 6A ). However, if the peptide were rotated around the central Gly (i.e., oriented as a retrobinder in the YJ34 binding site), then the Thr in position 6 would be placed into the pocket where Thr182 of switch 1 binds and the Thr 4 of YJ34 is predicted to bind. This would also position the Phe 4 of hit 2 above Tyr84 in RGS4 where Ile185 from switch 1 is located. These two amino acid interactions are reminiscent of a previously identified YJ34 analog, [Ac-Val-Lys-[Cys-Thr-Gly-Phe-Cys]-Glu-NH 2 , S-S, peptide 20 in Roof et al. (26) ], which has a Thr at position 4 and a Phe at position 6. This peptide inhibited RGS4 GAP activity by nearly 40% at 100 lM (26) . Thus, we propose that hit 2 interacts with RGS4 in the switch 1 binding site in an inverse orientation ( Figure 6 ). Based on our model, the Trp 8 residue of 2 also makes Although it is believed that hit 2 binds the YJ34 binding site, it is possible that some of the other peptides do not. In fact, the observation that many of them do not have an effect on GAP activity would suggest that this may be the case and that these analogs interact with RGS in alternate ways. This may explain why peptide 4, for example, bound RGS4 so well in the FACScan assay (Figure 3 ) while having little effect on RGS4 GAP activity (Figure 4 ). The RGS4 has been shown to have an allosteric site where phosphatidylinositol-3,4,5-trisphosphate (PIP3) and calmodulin are known to bind (43) . Calmodulin binding alone does not affect GAP activity, but blocks the inhibition by PIP3 (43) . It is therefore possible that some of the peptides isolated in the library bind RGS4 at this site without affecting RGS4 GAP activity. Alternatively, these peptides may bind other, perhaps as of yet unidentified, protein-protein interaction sites. The fact that the sequences obtained in the library are so divergent from the sequence of YJ34 also supports the possibility that many of the hit peptides do not bind at the YJ34 binding site. In fact, it is hard to find any clear structural clusters based on the homology of the varied positions. It is therefore speculated that RGS4 may have several peptide (and therefore endogenous protein or lipid) binding sites.
As in the YJ34 series, linear versions of hit 2 are inactive. In addition, as in the YJ34 series, hit 2 is most active on RGS4 compared with RGS7. It is thought that CCG-4986 inhibits RGS4 through cysteine modification [(32,35) , David Roman, personal communication, 2008]. Because of the apparent sensitivity of RGS4 to cysteine modifications, and because of cysteines in the peptides, it was examined whether a similar mechanism might exist here. Hence, peptides 2ad, 2nd, and YJ34 were tested against the -7Cys RGS4D51N mutant. The observation that none of the peptides differentiated between wild type and the -7C mutant supports a mechanism of action like that of YJ34, rather than via a covalent interaction with RGS4 cysteines. Novel Peptide RGS4 Inhibitors
